Taysha Secures Licence for UT Southwestern’s CLN7 Gene Therapy

Taysha Secures Licence for UT Southwestern’s CLN7 Gene Therapy

309139

Taysha Secures Licence for UT Southwestern’s CLN7 Gene Therapy

Taysha Gene Therapies has secured an exclusive option from the University of Texas Southwestern (UTSW) to license worldwide rights to a clinical-stage gene therapy program for CLN7 disease, a form of late-infantile Batten disease. A first-generation CLN7 therapy is currently being evaluated in a Phase 1 clinical trial (NCT04737460) run by the university, which is still enrolling patients. Top-line safety and efficacy data is expected by the end of the year. “The CLN7 program is…

You must be logged in to read/download the full post.